Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.

Author: CohanStanley, ElkinsJacob, GiovannoniGavin, GoldRalf, GreenbergSteven J, HavrdovaEva, MontalbanXavier, OzenGulden, RadueErnst-Wilhelm, SelmajKrzysztof, SprengerTill, StefoskiDusan, UmansKimberly

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. It was found to be safe and effective in patients with relapsing-remitting multiple sclerosis (RRMS).
Paper Details　
Original Abstract of the Article :
Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of daclizumab in patients with relapsing-remitting multiple sclerosis (RRMS). We report the long-ter...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962457/

データ提供：米国国立医学図書館（NLM）

Daclizumab for Relapsing-Remitting Multiple Sclerosis: A Long-Term Oasis of Hope

Relapsing-remitting multiple sclerosis (RRMS), a chronic and often debilitating autoimmune disease, presents a significant challenge for patients and clinicians alike. This study, like a camel navigating the unpredictable terrain of RRMS, examined the long-term safety and efficacy of daclizumab, a humanized monoclonal antibody, in patients with RRMS. The study's authors sought to provide insights into the long-term effectiveness and safety of this medication in managing this complex and often challenging disease.

Daclizumab: A Beacon of Hope in the Desert of MS

The study's findings, like a refreshing oasis in the desert, suggest that daclizumab, when administered at a dose of 150 mg subcutaneously every 4 weeks, can provide long-term benefits in managing RRMS. The study revealed that daclizumab was generally well-tolerated and demonstrated sustained efficacy in reducing relapse rates, suggesting its potential as a valuable treatment option for individuals with RRMS. This is like discovering a consistent source of water in the desert, providing sustained support and nourishment for a long journey.

Navigating the Challenges of MS: A Path to Improved Quality of Life

For individuals with RRMS, understanding the range of treatment options available is crucial for managing the disease and maintaining a good quality of life. This study highlights the potential of daclizumab to provide long-term benefits, reducing relapse rates and improving overall well-being. It's like finding a sturdy camel with a proven track record, capable of navigating the challenging landscape of MS with resilience and strength.

Dr. Camel's Conclusion

This study, like a guidepost pointing towards a promising oasis in the desert of MS research, provides valuable insights into the long-term safety and efficacy of daclizumab. The findings offer hope for individuals with RRMS, highlighting the potential of this medication to reduce relapse rates and improve overall quality of life. As a researcher, I am encouraged by the study's results and the potential they hold for advancing our understanding of RRMS and developing more effective treatment strategies.
Date :
  1. Date Completed 2016-12-13
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

27461166

DOI: Digital Object Identifier

PMC4962457

Related Literature

Article Analysis
・Effects of daclizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.